Genome-wide CRISPR activation screen in NB cells revealed that PIM1 drives resistance to ALK inhibitors brigatinib or ceritinib, and the combination of AZD1208 with ceritinib significantly delayed tumour growth in ALK mutant NB PDX models [292]. The gene discussed is ALK; the disease is neoplasm.